Clinical Trial Update: Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy

View source ↗

Summary

A clinical trial is evaluating the combination of PD-1/PD-L1 immune checkpoint inhibitors with radiotherapy across several cancers to assess clinical benefit an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Small Cell Lung Cancer
• Squamous Cell Carcinoma of the Skin
• Urothelial Carcinoma

Snippet

Sponsor: University of Erlangen-Nürnberg Medical School | Conditions: HNSCC, NSCLC | Status: RECRUITING